DOCSLIB.ORG

Towards a Peptide Implant : Analytics , Dry Heat Behavior and Functional Characterization

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

FACULTY OF PHARMACEUTICAL SCIENCES DRUG Quality & Registration (D RU QUA R) Lab TOWARDS A PEPTIDE IMPLANT : ANALYTICS , DRY HEAT BEHAVIOR AND FUNCTIONAL CHARACTERIZATION Thesis submitted to obtain the degree of Doctor in Pharmaceutical Sciences Matthias D’Hondt Promotor Prof. Dr. Bart DE SPIEGELEER FACULTY OF PHARMACEUTICAL SCIENCES Drug Quality & Registration (DruQuaR) Lab TOWARDS A PEPTIDE IMPLANT: ANALYTICS, DRY HEAT BEHAVIOR AND FUNCTIONAL CHARACTERIZATION Matthias D’HONDT Master of Science in Drug Development Promoter Prof. Dr. Apr. Bart DE SPIEGELEER 2015 Thesis submitted to obtain the degree of Doctor in Pharmaceutical Sciences COPYRIGHT COPYRIGHT The author and the promotor give the authorisation to consult and to copy parts of this thesis for personal use only. Any other use is limited by the Laws of Copyright, especially the obligation to refer to the source whenever results from this thesis are cited. Ghent, 16 January 2015 The promoto r The author Prof. Dr. Bart De Spiegeleer Matthias D’Hondt . 3 ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS Writing this doctoral thesis would have been impossible without the help and support of many people. First of all, I would like to thank my promoter, prof. Dr. Bart De Spiegeleer , for passing along or rather infecting me with his interests in peptide medicines and analytical technology. From our first meeting, his enthusiastic, stimulating and science-driven state-of-mind was immediately clear. Our countless discussions throughout the past few years have thought me invaluable lessons in numerous pharmaceutical (and other) aspects and were crucial for this work. It was a real honour completing this thesis under his guidance and hope that we may continue working together in the future, one way or the other. I also like to express my sincere gratitude to the members of the reading and examination committee (i.e. prof. Dr. Jean Paul Remon as chairman, prof. Dr. Deirdre Cabooter, prof. Dr. Catherine Delesalle, prof. Dr. Ralf Hoffmann, prof. Dr. Chris Vervaet, prof. Dr. Bruno De Geest and prof. Dr. Marleen Temmerman) for taking the time to read this work with a critical view; the fruitful, dynamic and open-minded discussions revealed aspects which were suited for improvement and truly pushed the quality of this thesis to a higher level. I would also like to acknowledge the Ghent University and IWT (Instituut voor Innovatie door Wetenschap en Technologie Vlaanderen; mandate 101529), who provided me with the necessary funding. Without their financial help, it would have been impossible for me to pursue and successfully complete this Ph.D. project. Next, I am grateful to my former DruQuaR colleagues Dr. Valentijn Vergote and Dr. Sylvia Van Dorpe, for familiarizing me with peptide mass spectrometry. Dr. Jente Boonen, Elien Vangheluwe and the previous lab technicians for guiding me during my first few months, teaching me the ropes of chromatography, and Dr. Bram Baert for introducing me into the quality assurance aspect of the DruQuaR lab. My gratitude also goes out to my present colle agues for their support during experiments and writing, scientific discussions, fun intermezzo’s and the general DruQuaR atmosphere: Dr. Evelien Wynendaele, Mathieu Verbeken, Nathalie Bracke, Sultan Suleman, Sofie Stalmans, Kirsten Vandercruyssen, Lieselotte Veryser, Lien Taevernier, Bert Gevaert, Frederick Verbeke, Han Hao, Xiaolong Xu and Marianne Lauwers. 5 ACKNOWLEDGEMENTS Furthermore, I would like to thank the people I worked with during our collaborations. I’m grateful to Bart De Spiegeleer Jr. for his help in the relative response factor calculations, Dr. Herwig Jansen (Dafra Pharma International), Dr. Ilse Koijen and Dr. Jacques van Gompel (both Janssen Pharmaceutica N.V) for providing necessary drug substances and their help in the AMES test experiments. I’m also indebted to Dr. Maria Fedorova (University of Leipzig, Faculty of Chemistry) for her help in identifying the peptide degradants and prof. Dr. Chien-Yu Peng (Academia Sinica, Institute of Statistical Science) for his contribution to the kinetic degradation models. I’m very thankful to Pieter Wuytens and prof. Dr. Andre Skirtach (UGhent, Department of Molecular Biotechnology) for the confocal Raman images of the implant and Dr. Steven Mullens (Flemish Institute for Technological Research (VITO)) for the R a determination of the mortar surfaces. I wish to thank my friends for providing timely distractions and sometimes showing me there’s more to life than work, be it at my tennis club or whilst attending a football game. Last but foremost, I wish to thank my family , especially my parents and sister, for their encouragement, help and support during this long “school” career and their understanding nature. Matthias 6 LIST OF ABBREVIATIONS AND SYMBOLS LIST OF ABBREVIATIONS AND SYMBOLS 2-MBT 2-mercaptobenzothiazole 2D-COSY 2D-correlated spectroscopy 2D-TOCSY 2D-total correlation spectroscopy A Frequency factor AA Amino acid Acm Acetamidomethyl ACN Acetonitrile ACTH Adrenocorticotropic hormone API Active Pharmaceutical Ingredient As Asymmetry factor BEH Bridged ethylene hybrid Bpa p-benzoylphenylalanine BSE Bovine spongiform encephalopathy BZL Benzyl CAGR Compound annual growth rate CAD Charged aerosol detection CCR5 C-C chemokine receptor type 5 CD Circular dichroism CD4 Cluster of differentiation 4 CE Capillary electrophoresis CLND Chemiluminescent nitrogen detection CPP Cell-penetrating peptide CRF Chromatographic response factor CSH Charged surface hybrid CXCR4 C-X-C chemokine receptor type 4 DIC Diisopropylcarbodiimide DMSO Dimethylsulfoxide Ea Activation energy EDQM European Directorate for the Quality of Medicines and HealthCare EDT Ethanedithiol ELSD Evaporative light scattering detection EMA European Medicines Agency 7 LIST OF ABBREVIATIONS AND SYMBOLS ENN Enniatin ESI Electrospray ionization EU European Union FA Formic acid FDA Food and Drug Administration FDP Finished drug product Fmoc Fluorenylmethyloxycarbonyl Fmoc-OSu Fluorenylmethoxycarbonyloxy succinimide FSH Follicle-stimulating hormone FT-ICT Fourier Transform Ion Cyclotron Resonance FTIR Fourier transform infrared FTN Flow through needle GMP Good manufacturing practice GnRH Gonadotropin-releasing hormone GP Glycoprotein HBTU O-Benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluorophosphate HCA Hierarchical Cluster Analysis HCMV Human cytomegalovirus HETP Height Equivalent to a Theoretical Plate HF Hydrofluoric acid HIV Human immunodeficiency virus HLB Hydrophilic-Lipophilic balance HME Hot-melt extrusion HPLC High Performance Liquid Chromatography HR Heptad repeat IBS Irritable bowel syndrome ICH International conference on harmonization ID Internal diameter IEC Ion-exchange chromatography IRDS Infant respiratory distress syndrome IS Internal standard IUPAC International Union of Pure and Applied Chemistry KPL Kinetic performance limit LC Liquid chromatography LH Luteinizing hormone 8 LIST OF ABBREVIATIONS AND SYMBOLS LoD Limit of detection LogD Distribution coefficient LoQ Limit of quantification MeOH Methanol MRM Multiple reaction monitoring MS Mass spectrometry MW Molecular weight NMR Nuclear magnetic resonance NOD2 Nucleotide-binding oligomerization domain-containing 2 Np Peak capacity OBt Benzotriazole ester ORD Optical rotation dispersion PC Peak capacity PC Principal Component PCA Principal Component Analysis PDA Photodiode array PEG Polyethylene glycol pEVA Poly(ethylene-vinylacetate) PG Protecting group Ph. Eur. European Pharmacopoeia Phg Phenylglycine pI Isoelectric point QC Quality control QbD Quality by design QSPR Quantitative structure-property relationship R&D Research and development RID Refractive index detector RMS Root mean square ROS Reactive oxygen species RP Reversed-phase RRT Relative retention times Rs corr Time-corrected resolution product S Separation factor S/N Signal to noise SBS Short bowel syndrome 9 LIST OF ABBREVIATIONS AND SYMBOLS SCX Strong cation exchange SEC Size-exclusion chromatography SEM Standard error on mean SER Surface-Enhanced Raman SFC Supercritical fluid chromatography SIM Selected ion monitoring SM Starting material SMILES Simplified Molecular Input Line Entry Specification SPC Summary of product characteristics SPE Solid-phase extraction SPP Superficially porous particle SPPS Solid-Phase Peptide Synthesis SST System suitability test p/v Peak to valley ratio PAT Process analytical technology PGA Polyglycolic acid PLA Polylactic acid PLGA Poly(lactide-co-glycolide) tBoc Tert-butyloxycarbonyl tBu Tertiary butyl TCS Tetracosactide TFA Trifluoroacetic acid TIC Total ion chromatogram TIS Triisopropylsilane TLC Thin-layer chromatography TSE Transmissible spongiform encephalopathy TQ-S Triple quadrupole mass spectrometer UPLC Ultra Performance Liquid Chromatography USA United States of America USP United States Pharmacopeia UV Ultraviolet VCD Vibrational circular dichroism WHO World Health Organisation WCX Weak cation exchange 10 TABLE OF CONTENTS TABLE OF CONTENTS Chapter I: Introduction 15 1. Peptides 17 2. Peptide stability 25 3. Peptide administration 26 4. Peptides with extended release potential 26 5. Peptide processing 29 6. Study objectives 30 7. Thesis outline 32 8. Referenc es 35 Chapter II: LC column selection: Derringer desirability and kinetic plots 39 1. Introduction 41 2. Materials and methods 43 3. Results and discussion 47 4. Conclusions 56 5. References 57 Chapter III: QC analysis of peptide APIs 59 1. Introduction 61 2. Materials and methods 62 3. Results 66 4. Discussion 72 5. Conclusions 75 6. References 77 Chapter IV: Peak
Recommended publications
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands

    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands

    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
  • Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin

    Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin

    0163-769X/04/$20.00/0 Endocrine Reviews 25(3):426–457 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/er.2002-0029 Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin AART J. VAN DER LELY, MATTHIAS TSCHO¨ P, MARK L. HEIMAN, AND EZIO GHIGO Division of Endocrinology and Metabolism (A.J.v.d.L.), Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands; Department of Psychiatry (M.T.), University of Cincinnati, Cincinnati, Ohio 45237; Endocrine Research Department (M.L.H.), Eli Lilly and Co., Indianapolis, Indiana 46285; and Division of Endocrinology (E.G.), Department of Internal Medicine, University of Turin, Turin, Italy 10095 Ghrelin is a peptide predominantly produced by the stomach. secretion, and influence on pancreatic exocrine and endo- Ghrelin displays strong GH-releasing activity. This activity is crine function as well as on glucose metabolism. Cardiovas- mediated by the activation of the so-called GH secretagogue cular actions and modulation of proliferation of neoplastic receptor type 1a. This receptor had been shown to be specific cells, as well as of the immune system, are other actions of for a family of synthetic, peptidyl and nonpeptidyl GH secre- ghrelin. Therefore, we consider ghrelin a gastrointestinal tagogues. Apart from a potent GH-releasing action, ghrelin peptide contributing to the regulation of diverse functions of has other activities including stimulation of lactotroph and the gut-brain axis. So, there is indeed a possibility that ghrelin corticotroph function, influence on the pituitary gonadal axis, analogs, acting as either agonists or antagonists, might have stimulation of appetite, control of energy balance, influence clinical impact.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • 1. Two Components, Two Sets of Lecturers

    1. Two Components, Two Sets of Lecturers

    Conditions 1. Two components, two sets of lecturers. 2. Lectures 1-5 Prof. F. Hudecz Lectures 6-9 Dr. Gy. Domány Lectures 10-12 Dr. P. Buzder-Lantos 3. Examination: two parts determined by the lecturers and one mark. - option A: written test - option B: presentation based on literature - option C: oral examination 4. Participation at lectures > 70 % [email protected] Some Approved Peptide Pharmaceuticals and their Methods of Manufacture First generatioin Second generation New generation Oxytocin (L) Carbetocin (S) Abarelix (GnRH) (L) ACTH (1-24) & (1-39) (L,S) Terlipressin (L,S) Cetrorelix (GnRH) (L) Vasopressin (L,S) Felypressin (L,S) Ganirelix (GnRH) (L) Insulin (E,SS, R) Buserelin (L,S) Eptifibatide Glucagon (E,S,R) Deslorelin (L,S) Bivalirudin (L) Calcitonins (L,S,R) Goserelin (L) Copaxone (L) TRH (L) Histrelin (L) Techtide P-289(S) Gonadorelin (L,S) Leuprolide (L,S) Cubicin (F) Somatostatin (L,S) Nafarelin (S) Fuzeon (antiHIV (H) GHRH (1-29) & (1-44) (S) Tryptorelin (L,S) Ziconotide (pain) (S) CRF (Human & Ovine) (S) Lecirelin (S) Pramlintide (diabetes) (S) Cyclosporin (F) Lanreotide (S) Exenatide (diabetes) (S) Thymopentin (L) Octreotide (L,S) Icatibant (brady-rec) Thymosin Alpha-1 (S) Atosiban (L) Romiplostim (hormon) Secretins (Human & Porcine) (E,S) Desmopressin (L,S) Degarelix (GnRH) Parathyroid Hormone (1-34) & (1-84)(S) Lypressin (L) Mifamurtide (rák, adj.) Vasoactive Intestinal Polypeptide (S) Ornipressin Ecallantide (ödéma) Brain Natriuretic Peptide (R) Pitressin (L) Liraglutide (diabetes) Cholecystokinin (L) ACE Inhibitors (Enalapril, Lisinopril) (L) Tesamorelin Tetragastrin (L) HIV Protease Inhibitors (L) Surfaxin Pentagastrin (L) Peginesatide Eledoisin (L) Carfilzomib Linaclotide (enz.inh) L = in solution; S = on solid phase; E = extraction; F = fermentation; H = hybrid synthesis; R = recombinant; SS = semi-synthesis.
  • Gattex Teduglutide Rdna Origin

    Gattex Teduglutide Rdna Origin

    Subject: Gattex (teduglutide [rDNA origin]) Original Effective Date: 5/30/2014 Policy Number: MCP-176 Revision Date(s): Review Date(s): 12/16/15; 9/15/2016; 6/22/2017 DISCLAIMER This Medical Policy is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina medical coverage policy (MCP) document and provide the directive for all Medicare members. FDA INDICATIONS � ∑ Short bowel syndrome: For the treatment of adult patients with short bowel syndrome who are dependent on parenteral support.
  • Gastric Secretory and Plasma Hormonal Responses to Sham-Feeding of Varying Duration in Patients with Duodenal Ulcer

    Gastric Secretory and Plasma Hormonal Responses to Sham-Feeding of Varying Duration in Patients with Duodenal Ulcer

    Gut: first published as 10.1136/gut.22.12.1003 on 1 December 1981. Downloaded from Gut, 1981, 22,1003-1010 Gastric secretory and plasma hormonal responses to sham-feeding of varying duration in patients with duodenal ulcer S J KONTUREK,* J SWIERCZEK, N KWIECIEN, W OBTUTOWICZ, M DOBRZANSKA, B KOPP, AND J OLEKSY From the Institute ofPhysiology, Medica, Academy, Krakow, and District Hospital, Krakow, Poland SUMMARY Gastric acid and serum gastrin, pancreatic polypeptide, and insulin responses to cephalic vagal stimulation were studied in eight patients with duodenal ulcer using modified sham- feeding for periods varying from four to 30 minutes. In addition, the maximal acid response to sham-feeding was compared with that induced by pentagastrin in 10 healthy subjects and 14 patients with duodenal ulcer. It was found that the gastric acid response to modified sham-feeding reached the maximal value after 15 minutes of sham-feeding and amounted to about 68% of the pentagastrin maximum. The serum pancreatic polypeptide response was also increased after modified sham-feeding and depended on the duration of this procedure, whereas gastrin and insulin responses were not significantly affected by modified sham-feeding. When the peak acid output induced by modified sham-feeding was normalised as percentage of the peak response to pentagastrin, it was similar in healthy subjects and in patients with duodenal ulcer; this indicates that the increased peak acid response to modified sham-feeding observed in patients with duodenal ulcer corresponded with
  • Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future

    Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future

    International Journal of Molecular Sciences Review Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future Anna Kathrin Stueven 1, Antonin Kayser 1, Christoph Wetz 2, Holger Amthauer 2, Alexander Wree 1, Frank Tacke 1, Bertram Wiedenmann 1, Christoph Roderburg 1,* and Henning Jann 1 1 Charité, Campus Virchow Klinikum and Charité, Campus Mitte, Department of Hepatology and Gastroenterology, Universitätsmedizin Berlin, 10117 Berlin, Germany; [email protected] (A.K.S.); [email protected] (A.K.); [email protected] (A.W.); [email protected] (F.T.); [email protected] (B.W.); [email protected] (H.J.) 2 Charité, Campus Virchow Klinikum and Charité, Campus Mitte, Department of Nuclear Medicine, Universitätsmedizin Berlin, 10117 Berlin, Germany; [email protected] (C.W.); [email protected] (H.A.) * Correspondence: [email protected]; Tel.: +49-30-450-553022 Received: 3 May 2019; Accepted: 19 June 2019; Published: 22 June 2019 Abstract: In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no longer available. Prognosis and survival of patients with NETs are determined by the location of the primary lesion, biochemical functional status, differentiation, initial staging, and response to treatment. Somatostatin analogue (SSA) therapy has been a mainstay of antisecretory therapy in functioning neuroendocrine tumors, which cause various clinical symptoms depending on hormonal hypersecretion. Beyond symptomatic management, recent research demonstrates that SSAs exert antiproliferative effects and inhibit tumor growth via the somatostatin receptor 2 (SSTR2).
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Study Protocol

    Study Protocol

    Cover Page for Protocol Sponsor name: Novo Nordisk A/S NCT number NCT02501161 Sponsor trial ID: NN9068-4228 Official title of study: A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus (DUAL™ VIII) Document date: 01 March 2019 IDegLira Date: 01 March 2019 Novo Nordisk Trial ID: NN9068-4228 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.1 16.1.1 Protocol and protocol amendments List of contents Protocol ............................................................................................................................................... Link Appendix A ......................................................................................................................................... Link Appendix B................................................................................................ .......................................... Link Attachment I and II............................................................................................................................ Link Protocol amendment 1 - MX ................................................................ ............................................. Link Protocol amendment 2 - NO.............................................................................................................. Link Protocol amendment 3 - Global/HQ ................................................................................................
  • Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

    Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

    Reviews/Commentaries/ADA Statements REVIEW ARTICLE Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits 1 4 DANIEL J. DRUCKER, MD RICHARD M. BERGENSTAL, MD ure, weight gain, and, in some analyses, 2 3 STEVEN I. SHERMAN, MD ROBERT S. SHERWIN, MD increased mortality with modest benefit 3 5 FRED S. GORELICK, MD JOHN B. BUSE, MD, PHD on rates of myocardial infarction. This has led to a re-examination of treatment recommendations to minimize the risk ype 2 diabetes is a complex meta- currently available agents exhibit the ideal of cardiovascular morbidity and mortal- bolic disorder characterized by profile of exceptional glucose-lowering ity (3,4) and specifically an interest in T hyperglycemia arising from a com- efficacy to safely achieve target levels of incretin-based therapies in this regard. bination of insufficient insulin secretion glycemia in a broad range of patients. together with resistance to insulin action. Hence, highly efficacious agents that ex- Incretin-based therapies: The incidence and prevalence of type 2 hibit unimpeachable safety, excellent tol- mechanisms of action and benefits diabetes are rising steadily, fuelled in part erability, and ease of administration to The two most recently approved classes of by a concomitant increase in the world- ensure long-term adherence and that also therapeutic agents for the treatment of wide rates of obesity. As longitudinal clearly reduce common comorbidities type 2 diabetes, glucagon-like peptide-1 studies of type 2 diabetes provide evi- and complications of diabetes are clearly (GLP-1) receptor (GLP-1R) agonists and dence linking improved glycemic control needed (Fig.
  • Prezentace Aplikace Powerpoint

    Prezentace Aplikace Powerpoint

    Hypothalamus and adenohypophysis functions. Neuroendocrine regulation THALAMUS - NON-SPECIFIC NUCLEI - SPECIFIC SENSORY NUCLEI - SPECIFIC NONSENSORY NUCLEI - ASSOCIATION NUCLEI HYPOTHALAMUS - SYSTEM OF SEVERAL DOZENS OF NUCLEI - PARAVENTRICULAR - MEDIAL - LATERAL REGION HYPOPHYSIS - PARS DISTALIS (STH, PRL, TSH, FSH, LH,ACTH) - PARS TUBERALIS (FSH, LH) - PARS INTERMEDIA (MSH) Behavior Ventrolateral medulla Hypothalamus (heart, stomach) Body temperature regulation Amygdala Neuroendocrine (associative regions of neocortex, regulation olfactory bulb, hippocampal formation, subcortical structures Appetitive behavior including brain stem) (hunger, thirst, sexual behavior) Hippocampus (associative regions of neocortex, Defensive reactions thalamus, reticular formation nuclei, etc.) Biorhythms and their regulation Nucleus solitarius (viscerosensory information– Autonomic nervous heart, lungs, GIT, blood vessels – system (modulation) baro-/chemoreceptors) Locus coeruleus (prefrontal cortex, N. Lamina terminalis Orbitofrontal cortex paragigantocellularis – integration of external and (blood, blood (sensory perception, reaction to composition) reward/punishment) autonomic stimuli – stress, panic) Circumventricular organs Eminentia mediana Subfornical organ Subcommissural organ - Afferent sensoric organ - Body fluid homeostasis - Mainly unknown function - Functional connection of - Blood pressure regulation (R for ANP and ATII) - R for neuropeptides and hypothalamus and hypophysis - Oxytocin secretion regulation neurotransmitters - Point of entry
  • Teduglutide for Treating Short Bowel Syndrome

    Teduglutide for Treating Short Bowel Syndrome

    Teduglutide for treating short bowel syndrome Produced by Aberdeen HTA Group Authors Graham Scotland1,2 Daniel Kopasker1 Neil Scott3 Moira Cruickshank1 Rodolfo Hernández 1 Cynthia Fraser1 Mairi McLean4 Alistair McKinlay5 Miriam Brazzelli2 1 Health Economics Research Unit, University of Aberdeen 2 Health Services Research Unit, University of Aberdeen 3 Medical Statistics Team, University of Aberdeen 4 School of Medicine, Medical Sciences & Nutrition, University of Aberdeen 5 Consultant Gastroenterologist, NHS Grampian Correspondence to Graham Scotland Senior Research Fellow University of Aberdeen Health Economics Research Unit Foresterhill, Aberdeen, AB25 2ZD Email: [email protected] Date completed 20 September 2017 Version 1 Copyright belongs to University of Aberdeen HTA Group, unless otherwise stated Copyright 2017 Queen's Printer and Controller of HMSO. All rights reserved. CONFIDENTIAL UNTIL PUBLISHED Source of funding: This report was commissioned by the NIHR HTA Programme as project number 15/07/04. Declared competing interests of the authors Alistair McKinley reports that he previously acted in a brief advisory capacity for Shire, through participation in an expert advisory meeting on short bowel syndrome in Scotland. All other authors have no competing interests to declare. Acknowledgements The authors are grateful to Lara Kemp for her administrative support. Copyright is retained by Shire for Tables 1, 3, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28 , 29, 39, 31, 32, and 33, and for Figures 1, 2, 5, 6 , 7, 9, 10, 11, and 12. Rider on responsibility for report The view expressed in this report are those of the authors and not necessarily those of the NIHR HTA Programme.